Double Bond Pharmaceutical International AB (DBP.B)

Overview

Double Bond Pharmaceutical International AB (publ) stands as a distinguished entity within the pharmaceutical industry, with its core operations revolving around the research, development, and commercialization of innovative therapeutic solutions aimed at combating oncological, infectious, autoimmune, and various life-threatening diseases. Having been established in 2014 and situated in Uppsala, Sweden, the company emerges as a beacon of hope, endeavoring to bridge the gap between current medical needs and future healthcare advancements.

Products and Services

Temodex: This represents a pioneering therapeutic approach designed specifically to combat malignant brain tumors. By focusing on the unique characteristics of these tumors, Temodex offers a potential lifeline to patients battling this aggressive form of cancer, presenting a new horizon in oncological treatment modalities.

SA033: Tailored to address the complexities of cancerous afflictions within the liver, SA033 embodies Double Bond Pharmaceutical's commitment to expanding the realm of cancer therapy. This product underscores the company's dedication to developing treatments that can significantly enhance the quality of life and survival rates of individuals facing liver cancers.

Belopenem: In the fight against bacterial pneumonia, Belopenem stands as a testament to Double Bond Pharmaceutical's innovative spirit in addressing infectious diseases. This developmental product aims to offer a reliable and effective treatment solution for battling this common yet potentially life-threatening condition, marking a crucial step forward in the company's infectious disease portfolio.